Cytosorbents Corp
CTSO
58 hedge funds and large institutions have $54.7M invested in Cytosorbents Corp in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 8 closing their positions.
1,133% more call options, than puts
Call options by funds: $74K | Put options by funds: $6K
73% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 11
6% more capital invested
Capital invested by funds: $51.3M → $54.7M (+$3.31M)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
0.19% less ownership
Funds ownership: 34.84% → 34.65% (-0.19%)
2% less funds holding
Funds holding: 59 → 58 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Avenir Corporation
Alexandria,
Virginia
|
+$519K |
| 2 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
+$225K |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$155K |
| 4 |
SC
Skylands Capital
Milwaukee,
Wisconsin
|
+$122K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$77.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$612K |
| 2 |
Jane Street
New York
|
-$211K |
| 3 |
Neuberger Berman Group
New York
|
-$187K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$133K |
| 5 |
E
Ergoteles
New York
|
-$68K |
CTSO Hedge Fund Activity: Q2 2023 in Review
58 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Cytosorbents Corp (CTSO) for Q2 2023, worth a combined $54.7M — up 6.4% from $51.3M a quarter earlier.
Fund positioning in CTSO was balanced in Q2 2023: 8 funds opened new positions, 8 closed out, 19 added to existing stakes and 11 trimmed.
The largest buyer was Avenir Corporation, adding an estimated $519K. The largest seller was Redmile Group, exiting entirely with an estimated $612K sold.
- 58 institutional investors held Cytosorbents Corp (CTSO) as of Q2 2023, down from 59 in Q1 2023.
- Funds reported $54.7M of Cytosorbents Corp stock for Q2 2023, up 6.4% quarter-over-quarter.
- 8 funds opened new Cytosorbents Corp positions in Q2 2023 and 8 closed out, a net change of 0 holders.
- The largest Cytosorbents Corp buyer in Q2 2023 was Avenir Corporation, an estimated $519K added.
- The largest Cytosorbents Corp seller in Q2 2023 was Redmile Group, an estimated $612K sold.
Based on aggregated 13F filings for Q2 2023.